Shares of Denali Therapeutics Inc (NASDAQ:DNLI) have been given a consensus recommendation of “Hold” by the six ratings firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $24.00.
Separately, Zacks Investment Research downgraded Denali Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 14th.
In related news, insider Carole Ho sold 17,500 shares of Denali Therapeutics stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $21.72, for a total value of $380,100.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Ryan J. Watts sold 18,333 shares of Denali Therapeutics stock in a transaction dated Tuesday, September 4th. The shares were sold at an average price of $19.06, for a total value of $349,426.98. The disclosure for this sale can be found here. In the last ninety days, insiders sold 54,167 shares of company stock worth $1,060,456. 21.30% of the stock is owned by company insiders.
Shares of DNLI traded down $0.57 during midday trading on Friday, hitting $14.15. The stock had a trading volume of 368,836 shares, compared to its average volume of 451,065. Denali Therapeutics has a twelve month low of $12.32 and a twelve month high of $25.79. The company has a market capitalization of $1.34 billion and a price-to-earnings ratio of -2.40.
Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Thursday, August 9th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.39). The business had revenue of $1.65 million during the quarter, compared to analysts’ expectations of $3.00 million. Research analysts expect that Denali Therapeutics will post -1.2 EPS for the current year.
Denali Therapeutics Company Profile
Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.